IL98528A0 - Pharmaceutical compositions containing hybrid for killing bladder cancer cells - Google Patents

Pharmaceutical compositions containing hybrid for killing bladder cancer cells

Info

Publication number
IL98528A0
IL98528A0 IL98528A IL9852891A IL98528A0 IL 98528 A0 IL98528 A0 IL 98528A0 IL 98528 A IL98528 A IL 98528A IL 9852891 A IL9852891 A IL 9852891A IL 98528 A0 IL98528 A0 IL 98528A0
Authority
IL
Israel
Prior art keywords
cancer cells
bladder cancer
pharmaceutical compositions
compositions containing
containing hybrid
Prior art date
Application number
IL98528A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL98528A0 publication Critical patent/IL98528A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Networks Using Active Elements (AREA)
IL98528A 1990-06-21 1991-06-17 Pharmaceutical compositions containing hybrid for killing bladder cancer cells IL98528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54228190A 1990-06-21 1990-06-21
US66926991A 1991-03-14 1991-03-14

Publications (1)

Publication Number Publication Date
IL98528A0 true IL98528A0 (en) 1992-07-15

Family

ID=27066985

Family Applications (1)

Application Number Title Priority Date Filing Date
IL98528A IL98528A0 (en) 1990-06-21 1991-06-17 Pharmaceutical compositions containing hybrid for killing bladder cancer cells

Country Status (15)

Country Link
US (1) US5690928A (ja)
EP (2) EP0868920A3 (ja)
JP (1) JPH0721000B2 (ja)
KR (1) KR920000332A (ja)
AT (1) ATE173274T1 (ja)
AU (1) AU645094B2 (ja)
CA (1) CA2044858A1 (ja)
DE (1) DE69130466T2 (ja)
DK (1) DK0467536T3 (ja)
ES (1) ES2122968T3 (ja)
FI (1) FI913058A7 (ja)
IE (1) IE912130A1 (ja)
IL (1) IL98528A0 (ja)
NO (1) NO303579B1 (ja)
PT (1) PT98048B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207798B1 (en) * 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
CA2112473A1 (en) * 1991-07-05 1993-01-21 Patricia A. Bacha Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
CA2146572A1 (en) * 1992-10-07 1994-04-14 Dorothy Marquis-Omer Controlled-ph formulation for intravesicular instillation of tgf–pe40 ab
ATE364315T1 (de) * 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
AU6920800A (en) * 1999-08-19 2001-03-13 Stem Cell Pharmaceuticals, Inc. Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
PL2382990T3 (pl) * 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
CN100436481C (zh) * 2003-08-18 2008-11-26 中国医学科学院基础医学研究所 含腺病毒E4orf4蛋白的靶向性抗肿瘤融合蛋白
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
ITUD20130127A1 (it) * 2013-10-04 2015-04-05 Danieli Off Mecc Impianto siderurgico per la produzione di prodotti metallici lunghi e relativo metodo di produzione
CN107580501A (zh) 2015-03-12 2018-01-12 维文蒂亚生物公司 用于靶向epcam阳性膀胱癌的给药策略
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
DE3587022T2 (de) * 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
IN165717B (ja) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
ATE133993T1 (de) * 1989-02-17 1996-02-15 Merck & Co Inc Protein-antikrebsmittel
IL93723A (en) * 1989-03-22 1997-02-18 Merck & Co Inc Cystein modified truncated pseudomonas exotoxin A

Also Published As

Publication number Publication date
AU645094B2 (en) 1994-01-06
FI913058L (fi) 1991-12-22
ES2122968T3 (es) 1999-01-01
FI913058A0 (fi) 1991-06-20
NO912418D0 (no) 1991-06-20
AU7918991A (en) 1992-01-02
EP0868920A2 (en) 1998-10-07
IE912130A1 (en) 1992-01-01
EP0467536A2 (en) 1992-01-22
DK0467536T3 (da) 1999-07-26
EP0467536B1 (en) 1998-11-11
ATE173274T1 (de) 1998-11-15
US5690928A (en) 1997-11-25
DE69130466T2 (de) 1999-06-02
JPH0592999A (ja) 1993-04-16
CA2044858A1 (en) 1991-12-22
NO303579B1 (no) 1998-08-03
PT98048A (pt) 1992-04-30
FI913058A7 (fi) 1991-12-22
EP0868920A3 (en) 1999-02-10
KR920000332A (ko) 1992-01-29
DE69130466D1 (de) 1998-12-17
NO912418L (no) 1991-12-23
PT98048B (pt) 1998-11-30
JPH0721000B2 (ja) 1995-03-08
EP0467536A3 (en) 1992-09-16

Similar Documents

Publication Publication Date Title
IL98528A0 (en) Pharmaceutical compositions containing hybrid for killing bladder cancer cells
BR9811716A (pt) Análogos de ciclosporina deuterados e o seu emprego como agentes de modulação imunológica
HUT50786A (en) Process for producing new condensed heterocyclic compounds and pharmaceutical compositions containing them as active components
HU9300418D0 (en) Method for producing new cyclo-sporines and pharmaceutical preparatives containing said compounds
HU9300850D0 (en) Sulphonamido-pyridine-2-carboxylic acid amides as well as sulphonamido-carbonyl- ones, their n-oxides, method for producing them and pharmaceutical preparatives containing them
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
NO954440D0 (no) 2 pyridylmetylenpolyazamakrocyklo-fosfonsyrer, komplekser og derivater derav, for anvendelse som kontrastmidler
ATE135712T1 (de) Polypeptid, dessen verfahren zur herstellung und dieses enthaltende pharmazeutische zusammensetzung und deren benutzung
AU6269890A (en) Pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation and the use thereof, and pharmaceuticals based on these compounds
IL93425A0 (en) Modified pseudomonas exotoxin,its production and pharmaceutical compositions containing it
CZ228195A3 (en) Derivatives of hydroxymethylfurazancarboxylic acid, process of their preparation, their use for treating cardiovascular diseases and a pharmaceutical composition containing thereof
FR2446839A1 (fr) Procede de purification de la gamma-globuline s-sulfonee
PL315150A1 (en) Psoriasis treatment process
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
EP0741143A3 (en) Fragments of fibroblast growth factor
ES1003038U (es) Dispositivo corrector de patologia vertebral
JPS56100773A (en) Nn*33*1**3***oxapentamethyleneaminoo ethylideneamino**2*4*66triiodobenzoyl**betaa aminooalphaamethylpropionitrile* its manufacture and its use
KR900014372A (ko) 티에닐피페라진 이의 제조방법 및 이를 함유하는 약제